[{"orgOrder":0,"company":"Cellipont Bioservices","sponsor":"Secretome Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Partnership","leadProduct":"STM-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Cellipont Bioservices","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellipont Bioservices \/ Secretome Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Cellipont Bioservices \/ Secretome Therapeutics"},{"orgOrder":0,"company":"Cellipont Bioservices","sponsor":"Mongoose Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Agreement","leadProduct":"MGB-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Cellipont Bioservices","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellipont Bioservices \/ Mongoose Bio","highestDevelopmentStatusID":"4","companyTruncated":"Cellipont Bioservices \/ Mongoose Bio"},{"orgOrder":0,"company":"Cellipont Bioservices","sponsor":"Marker Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Collaboration","leadProduct":"Neldaleucel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Cellipont Bioservices","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellipont Bioservices \/ Marker Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Cellipont Bioservices \/ Marker Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Cellipont Bioservices

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Specialty & Agro Chemical
                          Not Confirmed
                          Specialty & Agro Chemical
                          Not Confirmed

                          Details : Through the collaboration, Cellipont will provide technology transfer and cGMP manufacturing services to support the scale-up and production of MT-601 for Marker’s APOLLO study.

                          Product Name : MT-601

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          June 17, 2025

                          Lead Product(s) : Neldaleucel

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Marker Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          Specialty & Agro Chemical
                          Not Confirmed
                          Specialty & Agro Chemical
                          Not Confirmed

                          Details : Under this partnership, Cellipont will provide technology transfer, analytical method transfer, and cGMP manufacturing for the STM-01 for treating Heart Failure With Preserved Ejection Fraction.

                          Product Name : STM-01

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          January 22, 2025

                          Lead Product(s) : STM-01

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Secretome Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          03

                          Specialty & Agro Chemical
                          Not Confirmed
                          Specialty & Agro Chemical
                          Not Confirmed

                          Details : The agreement aims for the technology transfer, process development, and cGMP manufacture of Mongoose's autologous MGB-001 TCR-T cell therapy program.

                          Product Name : MGB-001

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          October 10, 2024

                          Lead Product(s) : MGB-001

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Mongoose Bio

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank